Novonesis Raises 2026 Outlook After 8% First-Half Sales Growth
Novonesis reported 8% organic sales growth — meaning revenue growth stripping out currency swings and acquisitions — for the first half of 2026, along with a 37.7% adjusted EBITDA margin (a measure of operating profit before interest, taxes, depreciation, and amortization). The biosolutions company raised its full-year organic sales growth outlook from 5–7% to 7–8% (Novonesis). Management also said the full-year adjusted EBITDA margin is now expected at the higher end of the 37–38% range.
The H1 results, released August 19, 2026, mark a clear step up from the company's initial 2026 guidance issued in February. That earlier outlook projected organic sales growth of 5–7% and an adjusted EBITDA margin of 37–38%, accounting for currency headwinds (Reuters). The upward revision means first-half momentum exceeded internal expectations by enough to lift both ends of the growth range by 200 basis points (two percentage points).
These results build on fiscal 2025, when Novonesis delivered 7% organic sales growth and a 37.1% adjusted EBITDA margin (Novonesis). That full-year result, announced February 25, 2026, came alongside a Reuters report that fourth-quarter sales had missed market forecasts as growth stalled in the agriculture, energy and technology business unit (Reuters). The H1 2026 rebound to 8% organic growth and margin expansion to 37.7% suggests that whatever softness affected that unit late last year has not derailed the broader trajectory.
The trajectory through 2025 provides useful context for the current acceleration. In H1 2025, Novonesis posted 9% organic sales growth and narrowed its full-year outlook range to 6–8% (Novonesis). By the first nine months of 2025, organic growth had moderated to 8% and management raised guidance to 7–8%, indicating mid-single-digit Q4 growth (Novonesis). The full-year landed at 7%. The H1 2026 print of 8% therefore represents a re-acceleration relative to the back half of 2025.
Margin dynamics warrant attention. The H1 2026 adjusted EBITDA margin of 37.7% is 60 basis points (0.6 percentage points) above the full-year 2025 figure of 37.1% and sits at the upper boundary of the guided 37–38% range. Management's expectation that the full-year margin will land at the high end of that range implies confidence that H2 margins will hold near current levels rather than compress, even as the company absorbs the currency headwinds flagged in February.
The 2030 financial targets announced in August 2025 provide the strategic frame for evaluating these results. Novonesis laid out ambitions for organic sales growth acceleration, margin expansion, and ROIC improvement (ROIC being return on invested capital — how efficiently the company turns investor money into profit). Growth is expected to be primarily volume-driven, including synergies from the Chr. Hansen–Novozymes combination, plus a modest annual price contribution of 1–2% (Novonesis). The H1 2026 results are consistent with that volume-led thesis, though one half does not validate a multi-year target.
A conference call held June 23, 2026 offered an educational deep-dive on Novonesis' Household Care business, covering the industry landscape, the company's position in the value chain, and growth drivers. While not a reporting event, the timing placed it roughly two months before the H1 release, giving investors a framework for interpreting the enzymes and biosolutions segments within the overall portfolio.
The broader context here is whether the H1 acceleration is sustainable or reflects favorable comparison periods. The Q4 2025 miss in the agriculture, energy and technology unit, flagged by Reuters, raises the question of whether that segment has recovered or whether growth concentration has shifted toward other units. The raised full-year guidance implies management sees the first-half run-rate as repeatable in the second half, not a transient spike. The margin signal is arguably the more telling data point: 37.7% in H1, with a full-year expectation at the high end of 37–38%, indicates operating leverage — the idea that as sales grow, profit grows faster because fixed costs are spread over more revenue — is working as designed despite currency drag. For a company whose 2030 targets depend on volume-led growth with only modest pricing, maintaining margin while accelerating the top line is the core thesis playing out. Whether it holds through H2 is the question the next set of quarterly numbers will answer.
